tirzepatide우선순위 낮음근거 검토기타
LITERATURE DETAIL · PMID 42572119
Predicted 10-Year Cardiovascular Disease Risk Reduction with Tirzepatide Use Over Three Years for Primary Prevention of Cardiovascular Disease in Obesity.
Predicted 10-Year Cardiovascular Disease Risk Reduction with Tirzepatide Use Over Three Years for Primary Prevention of Cardiovascular Disease in Obesity.
- 저자
- Naveed Sattar, Mamas Mamas, Runjia Li, Luis-Emilio García-Pérez, Kevin L Chen, Navneet Upadhyay
- 저널
- European journal of preventive cardiology
- 공개일
- 2026 Aug 10
- 연구 유형
- 기타
- DOI
- 10.1093/eurjpc/zwag408
문헌 요약
This post hoc analysis assessed the durability of tirzepatide for primary cardiovascular disease (CVD) prevention in obesity, based on predicted CVD risk, in the SURMOUNT-1 (SM-1) 3-year study. SM-1 was a phase 3, double-blind, randomised trial where individuals with obesity/overweight and prediabetes received tirzepatide (5, 10, 15 mg) or placebo for 176…
PV 검토 포인트
누적 안전성 근거로 분류하고 기존 시그널과의 일관성을 확인합니다.